The polyphenolic phytoalexin resveratrol (RSV) and its analogues have received tremendous attention over the past couple of decades because of a number of reports highlighting their benefits in vitro and in vivo in a variety of human disease models, including cardio- and neuroprotection, immune regulation, and cancer chemoprevention. These studies have underscored the high degree of diversity in terms of the signaling networks and cellular effector mechanisms that are affected by RSV. The activity of RSV has been linked to cell-surface receptors, membrane signaling pathways, intracellular signal-transduction machinery, nuclear receptors, gene transcription, and metabolic pathways. The promise shown by RSV has prompted heightened interest in studies aimed at translating these observations to clinical settings. In this review, we present a comprehensive account of the basic chemistry of RSV, its bioavailability, and its multiple intracellular target proteins and signaling pathways. Antioxid. Redox Signal. 11, 2851–2897.
AdhamiVM, AfaqF, AhmadN. Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun, 288:579–585. 2001.
2.
AfaqF, AdhamiVM, AhmadN. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol, 186:28–37. 2003.
3.
AggarwalBB, BhardwajA, AggarwalRS, SeeramNP, ShishodiaS, TakadaY. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24:2783–2840. 2004.
4.
AggarwalBB, ShishodiaS. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol, 71:1397–1421. 2006.
5.
AggarwalBB, ShishodiaS, SandurSK, PandeyMK, SethiG. Inflammation and cancer: how hot is the link?Biochem Pharmacol, 72:1605–1621. 2006.
6.
AgoT, SadoshimaJ. Thioredoxin1 as a negative regulator of cardiac hypertrophy. Antioxid Redox Signal, 9:679–687. 2007.
7.
AhmadA, SyedFA, SinghS, HadiSM. Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. Toxicol Lett, 159:1–12. 2005.
8.
AhmadKA, ClementMV, HanifIM, PervaizS. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res, 64:1452–1459. 2004.
9.
AhmadKA, ClementMV, PervaizS. Pro-oxidant activity of low doses of resveratrol inhibits hydrogen peroxide-induced apoptosis. Ann N Y Acad Sci, 1010:365–373. 2003.
10.
AlkhalafM. Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells. Pharmacology, 80:134–143. 2007.
11.
AlkhalafM. Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation. Eur J Cancer Prev, 16:334–341. 2007.
12.
AllenSW, MuellerL, WilliamsSN, QuattrochiLC, RaucyJ. The use of a high-volume screening procedure to assess the effects of dietary flavonoids on human cyp1a1 expression. Drug Metab Dispos, 29:1074–1079. 2001.
13.
AlmeidaL, Vaz-da-SilvaM, FalcaoA, SoaresE, CostaR, LoureiroAI, Fernandes-LopesC, RochaJF, NunesT, WrightL, Soares-da-SilvaP. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res, 53,suppl 1:S7–S15. 2009.
14.
AltieriDC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer, 8:61–70. 2008.
15.
AlviraD, Yeste-VelascoM, FolchJ, VerdaguerE, CanudasAM, PallasM, CaminsA. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience, 147:746–756. 2007.
16.
ArakiT, SasakiY, MilbrandtJ. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science, 305:1010–1013. 2004.
17.
ArnerES, HolmgrenA. The thioredoxin system in cancer. Semin Cancer Biol, 16:420–426. 2006.
18.
AsensiM, MedinaI, OrtegaA, CarreteroJ, BanoMC, ObradorE, EstrelaJM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med, 33:387–398. 2002.
19.
AshbyJ, TinwellH, PennieW, BrooksAN, LefevrePA, BeresfordN, SumpterJP. Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J Appl Toxicol, 19:39–45. 1999.
20.
AshfieldR, GribbleF, AshcroftS, AshcroftF. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel. Diabetes, 48:1341–1347. 1999.
21.
AshikawaK, MajumdarS, BanerjeeS, BhartiAC, ShishodiaS, AggarwalBB. Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol, 169:6490–6497. 2002.
22.
AttenMJ, AttarBM, MilsonT, HolianO. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem Pharmacol, 62:1423–1432. 2001.
23.
AttenMJ, Godoy-RomeroE, AttarBM, MilsonT, ZopelM, HolianO. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest New Drugs, 23:111–119. 2005.
24.
AustinMB, BowmanME, FerrerJL, SchroderJ, NoelJP. An aldol switch discovered in stilbene synthases mediates cyclization specificity of type III polyketide synthases. Chem Biol, 11:1179–1194. 2004.
25.
AziosNG, DharmawardhaneSF. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia, 7:128–140. 2005.
26.
AziosNG, KrishnamoorthyL, HarrisM, CubanoLA, CammerM, DharmawardhaneSF. Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. Neoplasia, 9:147–158. 2007.
27.
AzizMH, NihalM, FuVX, JarrardDF, AhmadN. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther, 5:1335–1341. 2006.
28.
AzmiAS, BhatSH, HadiSM. Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett, 579:3131–3135. 2005.
29.
BaatoutS, DerradjiH, JacquetP, MergeayM. Increased radiation sensitivity of an eosinophilic cell line following treatment with epigallocatechin-gallate, resveratrol and curcuma. Int J Mol Med, 15:337–352. 2005.
30.
BabichH, ReisbaumAG, ZuckerbraunHL. In vitro response of human gingival epithelial S-G cells to resveratrol. Toxicol Lett, 114:143–153. 2000.
31.
BackesjoCM, LiY, LindgrenU, HaldosenLA. Activation of sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs, 189:93–97. 2009.
32.
BaekSJ, WilsonLC, ElingTE. Resveratrol enhances the expression of non-steroidal antiinflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis, 23:425–434. 2002.
33.
BalestrieriML, RienzoM, FeliceF, RossielloR, GrimaldiV, MiloneL, CasamassimiA, ServilloL, FarzatiB, GiovaneA, NapoliC. High glucose downregulates endothelial progenitor cell number via SIRT1. Biochim Biophys Acta, 1784:936–945. 2008.
34.
BanerjeeS, Bueso-RamosC, AggarwalBB. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res, 62:4945–4954. 2002.
35.
BargerJL, KayoT, VannJM, AriasEB, WangJ, HackerTA, WangY, RaederstorffD, MorrowJD, LeeuwenburghC, AllisonDB, SaupeKW, CarteeGD, WeindruchR, ProllaTA. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE, 3:e2264. 2008.
36.
BaurJA, PearsonKJ, PriceNL, JamiesonHA, LerinC, KalraA, PrabhuVV, AllardJS, Lopez-LluchG, LewisK, PistellPJ, PoosalaS, BeckerKG, BossO, GwinnD, WangM, RamaswamyS, FishbeinKW, SpencerRG, LakattaEG, Le CouteurD, ShawRJ, NavasP, PuigserverP, IngramDK, de CaboR, SinclairDA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444:337–342. 2006.
37.
BaurJA, SinclairDA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov, 5:493–506. 2006.
38.
BeauseigneurF, GoubernM, ChapeyMF, GrestiJ, VergelyC, TsokoM, DemarquoyJ, RochetteL, ClouetP. F1F0-ATPase, early target of the radical initiator 2,2′-azobis-(2-amidinopropane) dihydrochloride in rat liver mitochondria in vitro. Biochem J, 320:571–576. 1996.
39.
BenitezDA, Pozo-GuisadoE, Alvarez-BarrientosA, Fernandez-SalgueroPM, CastellonEA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl, 28:282–293. 2007.
40.
BenitezDA, Pozo-GuisadoE, ClementiM, CastellonE, Fernandez-SalgueroPM. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer, 96:1595–1604. 2007.
BertelliAA, MiglioriM, PanichiV, LongoniB, OrigliaN, FerrettiA, CuttanoMG, GiovanniniL. Oxidative stress and inflammatory reaction modulation by white wine. Ann N Y Acad Sci, 957:295–301. 2002.
45.
BezstarostiK, DasS, LamersJM, DasDK. Differential proteomic profiling to study the mechanism of cardiac pharmacological preconditioning by resveratrol. J Cell Mol Med, 10:896–907. 2006.
46.
BhardwajA, SethiG, Vadhan-RajS, Bueso-RamosC, TakadaY, GaurU, NairAS, ShishodiaS, AggarwalBB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 109:2293–2302. 2007.
47.
BhatKP, PezzutoJM. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci, 957:210–229. 2002.
48.
BholaNE, GrandisJR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci, 13:1857–1865. 2008.
49.
BiancoNR, ChaplinLJ, MontanoMM. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem J, 385:279–287. 2005.
50.
BickenbachKA, VeerapongJ, ShaoMY, MauceriHJ, PosnerMC, KronSJ, WeichselbaumRR. Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther, 15:133–139. 2008.
51.
BillardC, IzardJC, RomanV, KernC, MathiotC, MentzF, KolbJP. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk Lymphoma, 43:1991–2002. 2002.
52.
BirrellMA, McCluskieK, WongS, DonnellyLE, BarnesPJ, BelvisiMG. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J, 19:840–841. 2005.
53.
Blanco-AparicioC, RennerO, LealJF, CarneroA. PTEN, more than the AKT pathway. Carcinogenesis, 28:1379–1386. 2007.
54.
Bobrowska-HagerstrandM, LillasM, MrowczynskaL, WrobelA, ShiratakiY, MotohashiN, HagerstrandH. Resveratrol oligomers are potent MRP1 transport inhibitors. Anticancer Res, 26:2081–2084. 2006.
BonawitzND, Chatenay-LapointeM, PanY, ShadelGS. Reduced TOR signaling extends chronological life span via increased respiration and upregulation of mitochondrial gene expression. Cell Metab, 5:265–277. 2007.
57.
BoocockDJ, FaustGE, PatelKR, SchinasAM, BrownVA, DucharmeMP, BoothTD, CrowellJA, PerloffM, GescherAJ, StewardWP, BrennerDE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev, 16:1246–1252. 2007.
58.
BorraMT, SmithBC, DenuJM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem, 280:17187–17195. 2005.
59.
BowersJL, TyulmenkovVV, JerniganSC, KlingeCM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology, 141:3657–3667. 2000.
60.
BradamanteS, BarenghiL, PiccininiF, BertelliAA, De JongeR, BeemsterP, De JongJW. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. Eur J Pharmacol, 465:115–123. 2003.
61.
BrakenhielmE, CaoR, CaoY. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J, 15:1798–1800. 2001.
62.
BritoPM, MarianoA, AlmeidaLM, DinisTC. Resveratrol affords protection against peroxynitrite-mediated endothelial cell death: a role for intracellular glutathione. Chem Biol Interact, 164:157–166. 2006.
63.
BrownGC. Nitric oxide and mitochondria. Front Biosci, 12:1024–1033. 2007.
64.
BruderJL, HsiehT, LereaKM, OlsonSC, WuJM. Induced cytoskeletal changes in bovine pulmonary artery endothelial cells by resveratrol and the accompanying modified responses to arterial shear stress. BMC Cell Biol, 2:1. 2001.
65.
BulucM, Demirel-YilmazE. Resveratrol decreases calcium sensitivity of vascular smooth muscle and enhances cytosolic calcium increase in endothelium. Vasc Pharmacol, 44:231–237. 2006.
66.
BurkeMA, MutharasanRK, ArdehaliH. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res, 102:164–176. 2008.
67.
BurkonA, SomozaV. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides: two novel resveratrol metabolites in human plasma. Mol Nutr Food Res, 52:549–557. 2008.
68.
BuryanovskyyL, FuY, BoydM, MaY, HsiehTC, WuJM, ZhangZ. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry, 43:11417–11426. 2004.
69.
BusquetsS, FusterG, AmetllerE, OlivanM, FiguerasM, CostelliP, CarboN, ArgilesJM, Lopez-SorianoFJ. Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clin Nutr, 26:239–244. 2007.
70.
CantoC, Gerhart-HinesZ, FeigeJN, LagougeM, NoriegaL, MilneJC, ElliottPJ, PuigserverP, AuwerxJ. AMPK regulates energy expenditure by modulating NAD(+) metabolism and SIRT1 activity. Nature, 458:1056–1060. 2009.
71.
CaoZ, FangJ, XiaC, ShiX, JiangBH. trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res, 10:5253–5263. 2004.
72.
CarmelietP. Angiogenesis in life, disease and medicine. Nature, 438:932–936. 2005.
73.
ChakrabortyPK, MustafiSB, GangulyS, ChatterjeeM, RahaS. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70. Cancer Sci, 99:1109–1116. 2008.
ChangTK, ChenJ, LeeWB. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther, 299:874–882. 2001.
76.
ChaoHH, JuanSH, LiuJC, YangHY, YangE, ChengTH, ShyuKG. Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. Eur J Pharmacol, 515:1–9. 2005.
77.
ChaoW, D'AmorePA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev, 19:111–120. 2008.
78.
ChenCY, JangJH, LiMH, SurhYJ. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun, 331:993–1000. 2005.
79.
ChenML, LiJ, XiaoWR, SunL, TangH, WangL, WuLY, ChenX, XieHF. Protective effect of resveratrol against oxidative damage of UVA irradiated HaCaT cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 31:635–639. 2006.
80.
ChenWP, ChiTC, ChuangLM, SuMJ. Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur J Pharmacol, 568:269–277. 2007.
81.
ChenWP, SuMJ, HungLM. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur J Pharmacol, 554:196–204. 2007.
82.
ChenZH, HurhYJ, NaHK, KimJH, ChunYJ, KimDH, KangKS, ChoMH, SurhYJ. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis, 25:2005–2013. 2004.
83.
ChiTC, ChenWP, ChiTL, KuoTF, LeeSS, ChengJT, SuMJ. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci, 80:1713–1720. 2007.
84.
ChoiJS, ChoiBC, KangKW. Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie, 64:49–52. 2009.
CullenJP, MorrowD, JinY, von Offenberg SweeneyN, SitzmannJV, CahillPA, RedmondEM. Resveratrol inhibits expression and binding activity of the monocyte chemotactic protein-1 receptor, CCR2, on THP-1 monocytes. Atherosclerosis, 195:e125–e133. 2007.
91.
DaiJM, WangZY, SunDC, LinRX, WangSQ. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol, 210:161–166. 2007.
92.
DaiZ, LiY, QuarlesLD, SongT, PanW, ZhouH, XiaoZ. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine, 14:806–814. 2007.
93.
DamianakiA, BakogeorgouE, KampaM, NotasG, HatzoglouA, PanagiotouS, GemetziC, KouroumalisE, MartinPM, CastanasE. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem, 78:429–441. 2000.
94.
DasS, CordisGA, MaulikN, DasDK. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol Heart Circ Physiol, 288:H328–H335. 2005.
95.
DasS, DasDK. Antiinflammatory responses of resveratrol. Inflamm Allergy Drug Targets, 6:168–173. 2007.
96.
DasS, FalchiM, BertelliA, MaulikN, DasDK. Attenuation of ischemia/reperfusion injury in rats by the antiinflammatory action of resveratrol. Arzneimittelforschung, 56:700–706. 2006.
97.
DasS, KhanN, MukherjeeS, BagchiD, GurusamyN, SwartzH, DasDK. Redox regulation of resveratrol-mediated switching of death signal into survival signal. Free Radic Biol Med, 44:82–90. 2008.
98.
DasS, TosakiA, BagchiD, MaulikN, DasDK. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther, 317:980–988. 2006.
99.
DasguptaB, MilbrandtJ. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A, 104:7217–7222. 2007.
100.
DaviesMA, Stemke-HaleK, TellezC, CalderoneTL, DengW, PrietoVG, LazarAJ, GershenwaldJE, MillsGB. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer, 99:1265–1268. 2008.
101.
Deak MaFH. On the chemistry of resveratrol diastereomers. Monat Chem, 134:883–888. 2003.
102.
DeBerardinisRJ, LumJJ, HatzivassiliouG, ThompsonCB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab, 7:11–20. 2008.
103.
DegnerSC, KempMQ, HockingsJK, RomagnoloDF. Cyclooxygenase-2 promoter activation by the aromatic hydrocarbon receptor in breast cancer mcf-7 cells: repressive effects of conjugated linoleic acid. Nutr Cancer, 59:248–257. 2007.
104.
DegtyarevM, De MaziereA, OrrC, LinJ, LeeBB, TienJY, PriorWW, van DijkS, WuH, GrayDC, DavisDP, SternHM, MurrayLJ, HoeflichKP, KlumpermanJ, FriedmanLS, LinK. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol, 183:101–116. 2008.
105.
DelavalB, BirnbaumD. A cell cycle hypothesis of cooperative oncogenesis [Review]Int J Oncol, 30:1051–1058. 2007.
106.
Della-MorteD, DaveKR, DefazioRA, BaoYC, RavalAP, Perez-PinzonMA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience, 159:993–1002. 2009.
107.
DelmasD, RebeC, MicheauO, AthiasA, GambertP, GrazideS, LaurentG, LatruffeN, SolaryE. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 23:8979–8986. 2004.
DochertyJJ, FuMM, HahJM, SweetTJ, FaithSA, BoothT. Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. Antiviral Res, 67:155–162. 2005.
110.
DochertyJJ, SweetTJ, BaileyE, FaithSA, BoothT. Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Res, 72:171–177. 2006.
111.
DolfiniE, RoncoroniL, DogliottiE, SalaG, ErbaE, SacchiN, GhidoniR. Resveratrol impairs the formation of MDA-MB-231 multicellular tumor spheroids concomitant with ceramide accumulation. Cancer Lett, 249:143–147. 2007.
112.
DongZ. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res, 523:145–150. 2003.
113.
DoraiT, AggarwalBB. Role of chemopreventive agents in cancer therapy. Cancer Lett, 215:129–140. 2004.
114.
DudleyJ, DasS, MukherjeeS, DasDK. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem, 20:443–452. 2008.
115.
El-MowafyAM. Resveratrol activates membrane-bound guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochem Biophys Res Commun, 291:1218–1224. 2002.
116.
El-MowafyAM, AlkhalafM. Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis, 24:869–873. 2003.
117.
El-MowafyAM, AlkhalafM, El-KashefHA. Resveratrol reverses hydrogen peroxide-induced proliferative effects in human coronary smooth muscle cells: a novel signaling mechanism. Arch Med Res, 39:155–161. 2008.
118.
El-MowafyAM, AlkhalafM, JaffalSM. Nongenomic activation of the GC-A enzyme by resveratrol and estradiol downstream from membrane estrogen receptors in human coronary arterial cells. Nutr Metab Cardiovasc Dis, 17:508–516. 2007.
FerrerJL, AustinMB, StewartCJr, NoelJP. Structure and function of enzymes involved in the biosynthesis of phenylpropanoids. Plant Physiol Biochem, 46:356–370. 2008.
125.
FioreM, FestaF, CornettaT, RicordyR, CozziR. Resveratrol affects X-ray induced apoptosis and cell cycle delay in human cells in vitro. Int J Mol Med, 15:1005–1012. 2005.
126.
FishelML, KelleyMR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med, 28:375–395. 2007.
127.
FitzGeraldGA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov, 2:879–890. 2003.
128.
FitzpatrickDF, HirschfieldSL, CoffeyRG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am J Physiol, 265:H774–H778. 1993.
129.
ForbesK, WestwoodM. The IGF axis and placental function: a mini review. Horm Res, 69:129–137. 2008.
130.
FrojdoS, CozzoneD, VidalH, PirolaL. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J, 406:511–518. 2007.
131.
FuggettaMP, LanzilliG, TricaricoM, CottarelliA, FalchettiR, RavagnanG, BonmassarE. Effect of resveratrol on proliferation and telomerase activity of human colon cancer cells in vitro. J Exp Clin Cancer Res, 25:189–193. 2006.
132.
FukuharaK, MiyataN. Resveratrol as a new type of DNA-cleaving agent. Bioorg Med Chem Lett, 8:3187–3192. 1998.
133.
FukuharaK, NagakawaM, NakanishiI, OhkuboK, ImaiK, UranoS, FukuzumiS, OzawaT, IkotaN, MochizukiM, MiyataN, OkudaH. Structural basis for DNA-cleaving activity of resveratrol in the presence of Cu(II)Bioorg Med Chem, 14:1437–1443. 2006.
134.
FuldaS, DebatinKM. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer, 41:786–798. 2005.
135.
FuldaS, DebatinKM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res, 64:337–346. 2004.
136.
FulgenziA, BertelliAA, MagniE, FerreroE, FerreroME. In vivo inhibition of TNFalpha-induced vascular permeability by resveratrol. Transplant Proc, 33:2341–2343. 2001.
137.
FustierP, Le CorreL, ChalabiN, Vissac-SabatierC, CommunalY, BignonYJ, Bernard-GallonDJ. Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines. Br J Cancer, 89:168–172. 2003.
138.
GallegosA, BerggrenM, GasdaskaJR, PowisG. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res, 57:4965–4970. 1997.
139.
GalluzziL, JozaN, TasdemirE, MaiuriMC, HengartnerM, AbramsJM, TavernarakisN, PenningerJ, MadeoF, KroemerG. No death without life: vital functions of apoptotic effectors. Cell Death Differ, 15:1113–1123. 2008.
140.
GaoZ, YeJ. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun, 376:793–796. 2008.
141.
GarberK. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst, 96:1805–1806. 2004.
142.
Gary-BoboM, NirdeP, JeanjeanA, MorereA, GarciaM. Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem, 14:2945–2953. 2007.
143.
GatzSA, KeimlingM, BaumannC, DorkT, DebatinKM, FuldaS, WiesmullerL. Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner. Carcinogenesis, 29:519–527. 2008.
144.
GehmBD, McAndrewsJM, ChienPY, JamesonJL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A, 94:14138–14143. 1997.
145.
GerhauserC, KlimoK, HeissE, NeumannI, Gamal-EldeenA, KnauftJ, LiuGY, SitthimonchaiS, FrankN. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res, 523–524:163–172. 2003.
146.
GinnanR, GuikemaBJ, HalliganKE, SingerHA, Jourd'heuilD. Regulation of smooth muscle by inducible nitric oxide synthase and NADPH oxidase in vascular proliferative diseases. Free Radic Biol Med, 44:1232–1245. 2008.
147.
GledhillJR, MontgomeryMG, LeslieAG, WalkerJE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci U S A, 104:13632–13637. 2007.
148.
Gojkovic-BukaricaL, NovakovicA, KanjuhV, BumbasirevicM, LesicA, HeinleH. A role of ion channels in the endothelium-independent relaxation of rat mesenteric artery induced by resveratrol. J Pharmacol Sci, 108:124–130. 2008.
149.
GolkarL, DingXZ, UjikiMB, SalabatMR, KellyDL, ScholtensD, FoughtAJ, BentremDJ, TalamontiMS, BellRH, AdrianTE. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res, 138:163–169. 2007.
150.
GolsteinP, AubryL, LevraudJP. Cell-death alternative model organisms: why and which?Nat Rev Mol Cell Biol, 4:798–807. 2003.
151.
GolsteinP, KroemerG. A multiplicity of cell death pathways: symposium on apoptotic and non-apoptotic cell death pathways. EMBO Rep, 8:829–833. 2007.
152.
GreenbergDA, JinK. From angiogenesis to neuropathology. Nature, 438:954–959. 2005.
153.
GuarenteL. Diverse and dynamic functions of the Sir silencing complex. Nat Genet, 23:281–285. 1999.
154.
GuarenteL. Mitochondria: a nexus for aging, calorie restriction, and sirtuins?Cell, 132:171–176. 2008.
155.
HaiderUG, RoosTU, KontaridisMI, NeelBG, SorescuD, GriendlingKK, VollmarAM, DirschVM. Resveratrol inhibits angiotensin II- and epidermal growth factor-mediated Akt activation: role of Gab1 and Shp2. Mol Pharmacol, 68:41–48. 2005.
156.
HaiderUG, SorescuD, GriendlingKK, VollmarAM, DirschVM. Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol Pharmacol, 63:925–932. 2003.
157.
HaiderUG, SorescuD, GriendlingKK, VollmarAM, DirschVM. Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol Pharmacol, 62:772–777. 2002.
HalazonetisTD, GorgoulisVG, BartekJ. An oncogene-induced DNA damage model for cancer development. Science, 319:1352–1355. 2008.
160.
HambrockA, de Oliveira FranzCB, HillerS, GrenzA, AckermannS, SchulzeDU, DrewsG, OsswaldH. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J Biol Chem, 282:3347–3356. 2007.
161.
HandlerN, BrunhoferG, StudenikC, LeisserK, JaegerW, ParthS, ErkerT. “Bridged” stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem, 15:6109–6118. 2007.
162.
HarperCE, PatelBB, WangJ, ArabshahiA, EltoumIA, LamartiniereCA. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis, 28:1946–1953. 2007.
163.
HassaPO, HottigerMO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci, 13:3046–3082. 2008.
164.
HavensCG, HoA, YoshiokaN, DowdySF. Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol Cell Biol, 26:4701–4711. 2006.
165.
HaworthRS, AvkiranM. Inhibition of protein kinase D by resveratrol. Biochem Pharmacol, 62:1647–1651. 2001.
166.
HayashibaraT, YamadaY, NakayamaS, HarasawaH, TsurudaK, SugaharaK, MiyanishiT, KamihiraS, TomonagaM, MaitaT. Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer, 44:193–201. 2002.
167.
HeS, JiangL, WuB, PanY, SunC. Pallidol, a resveratrol dimer from red wine, is a selective singlet oxygen quencher. Biochem Biophys Res Commun, 379:283–287. 2009.
168.
HeeresJT, HergenrotherPJ. Poly(ADP-ribose) makes a date with death. Curr Opin Chem Biol, 11:644–653. 2007.
169.
HeissEH, SchilderYD, DirschVM. Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J Biol Chem, 282:26759–26766. 2007.
170.
HeitB, RobbinsSM, DowneyCM, GuanZ, ColarussoP, MillerBJ, JirikFR, KubesP. PTEN functions to ‘prioritize’ chemotactic cues and prevent ‘distraction’ in migrating neutrophils. Nat Immunol, 9:743–752. 2008.
171.
HennessyBT, SmithDL, RamPT, LuY, MillsGB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov, 4:988–1004. 2005.
172.
HerediaA, DavisC, RedfieldR. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acquir Immune Defic Syndr, 25:246–255. 2000.
173.
HockenberyD, NunezG, MillimanC, SchreiberRD, KorsmeyerSJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348:334–336. 1990.
174.
HongSP, ChoiDH, ChoiJS. Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. Cardiovasc Ther, 26:269–275. 2008.
HsiehTC, BurfeindP, LaudK, BackerJM, TraganosF, DarzynkiewiczZ, WuJM. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int J Oncol, 15:245–252. 1999.
177.
HsiehTC, LuX, WangZ, WuJM. Induction of quinone reductase NQO1 by resveratrol in human K562 cells involves the antioxidant response element ARE and is accompanied by nuclear translocation of transcription factor Nrf2. Med Chem, 2:275–285. 2006.
178.
HsiehTC, WangZ, HambyCV, WuJM. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun, 334:223–230. 2005.
179.
HuangC, MaWY, GoransonA, DongZ. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis, 20:237–242. 1999.
180.
HuangH, ReganKM, WangF, WangD, SmithDI, van DeursenJM, TindallDJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A, 102:1649–1654. 2005.
181.
HuangH, TindallDJ. FOXO factors: a matter of life and death. Future Oncol, 2:83–89. 2006.
182.
HuangJ, GanQ, HanL, LiJ, ZhangH, SunY, ZhangZ, TongT. SIRT1 Overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS ONE, 3:e1710. 2008.
183.
HuangYL, LokeSH, HsuCC, ChiouWF. (+)-Vitisin A inhibits influenza A virus-induced RANTES production in A549 alveolar epithelial cells through interference with Akt and STAT1 phosphorylation. Planta Med, 74:156–162. 2008.
184.
HunterT. 1001 protein kinases redux: towards 2000. Semin Cell Biol, 5:367–376. 1994.
185.
HwangJT, KwakDW, LinSK, KimHM, KimYM, ParkOJ. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann N Y Acad Sci, 1095:441–448. 2007.
IanariA, NataleT, CaloE, FerrettiE, AlesseE, ScrepantiI, HaigisK, GulinoA, LeesJA. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell, 15:184–194. 2009.
188.
ImaiS, ArmstrongCM, KaeberleinM, GuarenteL. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 403:795–800. 2000.
189.
ImlerTJJr, PetroTM. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(−) IFN-gamma+ cells, and decreased macrophage IL-6 expression. Int Immunopharmacol, 9:134–143. 2009.
190.
IndraccoloS, FavaroE, AmadoriA. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle, 5:1751–1755. 2006.
191.
InfangerDW, SharmaRV, DavissonRL. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal, 8:1583–1596. 2006.
192.
InoueK, WenR, RehgJE, AdachiM, ClevelandJL, RousselMF, SherrCJ. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev, 14:1797–1809. 2000.
193.
IssureePDA, PushparajPN, PervaizS, MelendezAJ. Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. FASEB J, 2009April 13. [Epub ahead of print].
194.
IyoriM, KataokaH, ShamsulHM, KiuraK, YasudaM, NakataT, HasebeA, ShibataK. Resveratrol modulates phagocytosis of bacteria through an NF-{kappa}B-dependent gene program. Antimicrob Agents Chemother, 52:121–127. 2008.
195.
JacobC, HolmeAL, FryFH. The sulfinic acid switch in proteins. Org Biomol Chem, 2:1953–1956. 2004.
196.
JamesJS. Resveratrol: why it matters in HIV. AIDS Treat News, 3–5. 2006.
197.
JangM, CaiL, UdeaniGO, SlowingKV, ThomasCF, BeecherCW, FongHH, FarnsworthNR, KinghornAD, MehtaRG, MoonRC, PezzutoJM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275:218–220. 1997.
198.
JangM, PezzutoJM. Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett, 134:81–89. 1998.
199.
JanickeRU, SohnD, Schulze-OsthoffK. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ, 15:959–976. 2008.
200.
JeongWS, KimIW, HuR, KongAN. Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm Res, 21:649–660. 2004.
201.
JeongWS, KimIW, HuR, KongAN. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res, 21:661–670. 2004.
202.
JhumkaZ, PervaizS, ClementMV. Resveratrol regulates the expression of NHE-1 by repressing its promoter activity: critical involvement of intracellular H(2)O(2) and caspases 3 and 6 in the absence of cell death. Int J Biochem Cell Biol, 41:945–956. 2009.
203.
JoJY, Gonzalez de MejiaE, LilaMA. Catalytic inhibition of human DNA topoisomerase II by interactions of grape cell culture polyphenols. J Agric Food Chem, 54:2083–2087. 2006.
204.
JoJY, Gonzalez de MejiaE, LilaMA. Effects of grape cell culture extracts on human topoisomerase II catalytic activity and characterization of active fractions. J Agric Food Chem, 53:2489–2498. 2005.
JonesDT, PughCW, WigfieldS, StevensMF, HarrisAL. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin Cancer Res, 12:5384–5394. 2006.
207.
JuricD, WojciechowskiP, DasDK, NetticadanT. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol, 292:H2138–H2143. 2007.
208.
KaeberleinM, McVeyM, GuarenteL. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev, 13:2570–2580. 1999.
209.
KagaS, ZhanL, MatsumotoM, MaulikN. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol, 39:813–822. 2005.
210.
KakolyrisS, GiatromanolakiA, KoukourakisM, PowisG, SouglakosJ, SivridisE, GeorgouliasV, GatterKC, HarrisAL. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res, 7:3087–3091. 2001.
211.
KaldasMI, WalleUK, WalleT. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol, 55:307–312. 2003.
212.
KamholzSL. Wine, spirits and the lung: good, bad or indifferent?Trans Am Clin Climatol Assoc, 117:129–145discussion 145, 2006.
213.
Karine Ferré-FilmonLD, AlbertDemonceau, AlfredF. Noels. Catalytic methods for the synthesis of stilbenes with an emphasis on their phytoalexins. Coord Chem Rev, 248:2323–2336. 2004.
214.
KawaharaTL, MichishitaE, AdlerAS, DamianM, BerberE, LinM, McCordRA, OngaiguiKC, BoxerLD, ChangHY, ChuaKF. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell, 136:62–74. 2009.
215.
KawajiriK, Fujii-KuriyamaY. Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. Arch Biochem Biophys, 464:207–212. 2007.
216.
KennedyBK, AustriacoNRJr, ZhangJ, GuarenteL. Mutation in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell, 80:485–496. 1995.
217.
KimD, NguyenMD, DobbinMM, FischerA, SananbenesiF, RodgersJT, DelalleI, BaurJA, SuiG, ArmourSM, PuigserverP, SinclairDA, TsaiLH. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J, 26:3169–3179. 2007.
218.
KimDH, AhnT, JungHC, PanJG, YunCH. Generation of the human metabolite piceatannol from the anti-cancer preventive agent resveratrol by bacterial cytochrome P450 Bm3. Drug Metab Dispos, 37:932–936. 2009.
219.
KimYA, RheeSH, ParkKY, ChoiYH. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food, 6:273–280. 2003.
220.
KluthD, BanningA, PaurI, BlomhoffR, Brigelius-FloheR. Modulation of pregnane X receptor- and electrophile responsive element-mediated gene expression by dietary polyphenolic compounds. Free Radic Biol Med, 42:315–325. 2007.
221.
KobayashiY, Furukawa-HibiY, ChenC, HorioY, IsobeK, IkedaK, MotoyamaN. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med, 16:237–243. 2005.
222.
Kolthur-SeetharamU, DantzerF, McBurneyMW, de MurciaG, Sassone-CorsiP. Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle, 5:873–877. 2006.
223.
KondoN, NakamuraH, MasutaniH, YodoiJ. Redox regulation of human thioredoxin network. Antioxid Redox Signal, 8:1881–1890. 2006.
224.
KothaA, SekharamM, CilentiL, SiddiqueeK, KhaledA, ZervosAS, CarterB, TurksonJ, JoveR. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther, 5:621–629. 2006.
225.
KrishnanV, ZeichnerSL. Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency. J Virol, 78:9458–9473. 2004.
226.
KubotaT, UemuraY, KobayashiM, TaguchiH. Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res, 23:4039–4046. 2003.
227.
KueckA, OpipariAWJr., GriffithKA, TanL, ChoiM, HuangJ, WahlH, LiuJR. Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol, 107:450–457. 2007.
228.
KumarP, PadiSS, NaiduPS, KumarA. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol, 17:485–492. 2006.
229.
KunE, KirstenE, HakamA, BauerPI, MendeleyevJ. Identification of poly(ADP-ribose) polymerase-1 as the OXPHOS-generated ATP sensor of nuclei of animal cells. Biochem Biophys Res Commun, 366:568–573. 2008.
230.
KunduJK, ShinYK, KimSH, SurhYJ. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis, 27:1465–1474. 2006.
231.
KunduJK, ShinYK, SurhYJ. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochem Pharmacol, 72:1506–1515. 2006.
232.
KuwajerwalaN, CifuentesE, GautamS, MenonM, BarrackER, ReddyGP. Resveratrol induces prostate cancer cell entry into S phase and inhibits DNA synthesis. Cancer Res, 62:2488–2492. 2002.
233.
KyselovaV, PeknicovaJ, BuckiovaD, BoubelikM. Effects of p-nonylphenol and resveratrol on body and organ weight and in vivo fertility of outbred CD-1 mice. Reprod Biol Endocrinol, 1:30. 2003.
234.
LagougeM, ArgmannC, Gerhart-HinesZ, MezianeH, LerinC, DaussinF, MessadeqN, MilneJ, LambertP, ElliottP, GenyB, LaaksoM, PuigserverP, AuwerxJ. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127:1109–1122. 2006.
235.
LanconA, DelmaD, OsmanH, ThenotJP, JanninB, LatruffeN. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun, 316:1132–1137. 2004.
236.
LanzilliG, FuggettaMP, TricaricoM, CottarelliA, SerafinoA, FalchettiR, RavagnanG, TurrizianiM, AdamoR, FranzeseO, BonmassarE. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol, 28:641–648. 2006.
237.
Le CorreL, FustierP, ChalabiN, BignonYJ, Bernard-GallonD. Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin Chim Acta, 344:115–121. 2004.
238.
LeeB, MoonSK. Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells. J Nutr, 135:2767–2773. 2005.
LeeKW, KangNJ, HeoYS, RogozinEA, PuglieseA, HwangMK, BowdenGT, BodeAM, LeeHJ, DongZ. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res, 68:946–955. 2008.
241.
LeeMK, KangSJ, PonczM, SongKJ, ParkKS. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med, 39:376–384. 2007.
242.
LeeSC, ChanJ, ClementMV, PervaizS. Functional proteomics of resveratrol-induced colon cancer cell apoptosis: caspase-6-mediated cleavage of lamin A is a major signaling loop. Proteomics, 6:2386–2394. 2006.
243.
LeiroJ, AlvarezE, ArranzJA, LagunaR, UriarteE, OralloF. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol, 75:1156–1165. 2004.
244.
LekliI, SzaboG, JuhaszB, DasS, DasM, VargaE, SzendreiL, GesztelyiR, VaradiJ, BakI, DasDK, TosakiA. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol, 294:H859–H866. 2008.
245.
LeonardSS, XiaC, JiangBH, StinefeltB, KlandorfH, HarrisGK, ShiX. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun, 309:1017–1026. 2003.
246.
LetenneurL. Risk of dementia and alcohol and wine consumption: a review of recent results. Biol Res, 37:189–193. 2004.
247.
LevitzkiA. Cross-talk between PKC and cyclic AMP pathways. Nature, 330:319–320. 1987.
LiX, ZhangS, SafeS. Activation of kinase pathways in MCF-7 cells by 17beta-estradiol and structurally diverse estrogenic compounds. J Steroid Biochem Mol Biol, 98:122–132. 2006.
250.
LiYQ, LiZL, ZhaoWJ, WenRX, MengQW, ZengY. Synthesis of stilbene derivatives with inhibition of SARS coronavirus replication. Eur J Med Chem, 41:1084–1089. 2006.
LimCP, CaoX. Structure, function, and regulation of STAT proteins. Mol Biosyst, 2:536–550. 2006.
253.
LimKH, AncrileBB, KashatusDF, CounterCM. Tumour maintenance is mediated by eNOS. Nature, 452:646–649. 2008.
254.
LinHY, LansingL, MerillonJM, DavisFB, TangHY, ShihA, VitracX, KrisaS, KeatingT, CaoHJ, BerghJ, QuackenbushS, DavisPJ. Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J, 20:1742–1744. 2006.
255.
LinJ, ReichnerC, WuX, LevineAJ. Analysis of wild-type and mutant p21WAF-1 gene activities. Mol Cell Biol, 16:1786–1793. 1996.
256.
LinSJ, DefossezPA, GuarenteL. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science, 289:2126–2128. 2000.
257.
LiuQ, XieF, RolstonR, MoreiraPI, NunomuraA, ZhuX, SmithMA, PerryG. Prevention and treatment of Alzheimer disease and aging: antioxidants. Mini Rev Med Chem, 7:171–180. 2007.
LiuYV, SemenzaGL. RACK1 vs. HSP90: competition for HIF-1 Epub 2007 Mar 7. Alpha degradation vs. stabilization. Cell Cycle, 6:656–659Epub 2007 Mar 7.
260.
LiuZ, LenardoMJ. Reactive oxygen species regulate autophagy through redox-sensitive proteases. Dev Cell, 12:484–485. 2007.
261.
LuR, SerreroG. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol, 179:297–304. 1999.
262.
LuZ, ZhangY, LiuH, YuanJ, ZhengZ, ZouG. Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin. J Fluoresc, 17:580–587. 2007.
263.
MaZH, MaQY, WangLC, ShaHC, WuSL, ZhangM. Effect of resveratrol on NF-kappaB activity in rat peritoneal macrophages. Am J Chin Med, 34:623–630. 2006.
264.
MacCarroneM, LorenzonT, GuerrieriP, AgroAF. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem, 265:27–34. 1999.
265.
Mahyar-RoemerM, KatsenA, MestresP, RoemerK. Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int J Cancer, 94:615–622. 2001.
266.
MaillietF, FerryG, VellaF, BergerS, CogeF, ChomaratP, MalletC, GueninSP, GuillaumetG, Viaud-MassuardMC, YousS, DelagrangeP, BoutinJA. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol, 71:74–88. 2005.
267.
MannaSK, MukhopadhyayA, AggarwalBB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol, 164:6509–6519. 2000.
268.
MaoC, ObeidLM. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta, 1781:424–434. 2008.
MarierJF, VachonP, GritsasA, ZhangJ, MoreauJP, DucharmeMP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther, 302:369–373. 2002.
271.
MarkL, NikfardjamMS, AvarP, OhmachtR. A validated HPLC method for the quantitative analysis of trans-resveratrol and trans-piceid in Hungarian wines. J Chromatogr Sci, 43:445–449. 2005.
Martin-GronertMS, Tarry-AdkinsJL, CrippsRL, ChenJH, OzanneSE. Maternal protein restriction leads to early life alterations in the expression of key molecules involved in the aging process in rat offspring. Am J Physiol Regul Integr Comp Physiol, 294:R494–R500. 2008.
274.
MartinezJ, MorenoJJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol, 59:865–870. 2000.
275.
MatsutaniY, YamauchiA, TakahashiR, UenoM, YoshikawaK, HondaK, NakamuraH, KatoH, KodamaH, InamotoT, YodoiJ, YamaokaY. Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res, 7:3430–3436. 2001.
276.
MatsuzawaA, IchijoH. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta, 1780:1325–1336. 2008.
277.
MikstackaR, PrzybylskaD, RimandoAM, Baer-DubowskaW. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol Nutr Food Res, 51:517–524. 2007.
278.
MilneJC, LambertPD, SchenkS, CarneyDP, SmithJJ, GagneDJ, JinL, BossO, PerniRB, VuCB, BemisJE, XieR, DischJS, NgPY, NunesJJ, LynchAV, YangH, GalonekH, IsraelianK, ChoyW, IfflandA, LavuS, MedvedikO, SinclairDA, OlefskyJM, JirousekMR, ElliottPJ, WestphalCH. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 450:712–716. 2007.
279.
MilosoM, BertelliAA, NicoliniG, TrediciG. Resveratrol-induced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci Lett, 264:141–144. 1999.
280.
MnjoyanZH, FujiseK. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/CIP1) pathway. Biochem Biophys Res Commun, 311:546–552. 2003.
281.
MohanJ, GandhiAA, BhavyaBC, RashmiR, KarunagaranD, InduR, SanthoshkumarTR. Caspase-2 triggers Bax-Bak-dependent and -independent cell death in colon cancer cells treated with resveratrol. J Biol Chem, 281:17599–17611. 2006.
282.
MokniM, ElkahouiS, LimamF, AmriM, AouaniE. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res, 32:981–987. 2007.
283.
MonteiroP, GilotD, Le FerrecE, RauchC, Lagadic-GossmannD, FardelO. Dioxin-mediated up-regulation of aryl hydrocarbon receptor target genes is dependent on the calcium/calmodulin/CaMKIalpha pathway. Mol Pharmacol, 73:769–777. 2008.
MuriasM, HandlerN, ErkerT, PlebanK, EckerG, SaikoP, SzekeresT, JagerW. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem, 12:5571–5578. 2004.
288.
NaesensL, BonnafousP, AgutH, De ClercqE. Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. J Clin Virol, 37,suppl 1:S69–S75. 2006.
289.
NagaseM, AndoK, NagaseT, KanameS, SawamuraT, FujitaT. Redox-sensitive regulation of lox-1 gene expression in vascular endothelium. Biochem Biophys Res Commun, 281:720–725. 2001.
290.
NakabeppuY, TsuchimotoD, FuruichiM, SakumiK. The defense mechanisms in mammalian cells against oxidative damage in nucleic acids and their involvement in the suppression of mutagenesis and cell death. Free Radic Res, 38:423–429. 2004.
NarayananBA. Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr Cancer Drug Targets, 6:711–727. 2006.
293.
NarayananBA, NarayananNK, ReGG, NixonDW. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer, 104:204–212. 2003.
294.
NarayananBA, NarayananNK, StonerGD, BullockBP. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci, 70:1821–1839. 2002.
295.
NemotoS, FergussonMM, FinkelT. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science, 306:2105–2108. 2004.
296.
NiereM, KernstockS, Koch-NolteF, ZieglerM. Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix. Mol Cell Biol, 28:814–824. 2008.
297.
NifliAP, KampaM, AlexakiVI, NotasG, CastanasE. Polyphenol interaction with the T47D human breast cancer cell line. J Dairy Res, 72 Spec No:44–50. 2005.
298.
NikaidoY, YoshizawaK, DanbaraN, Tsujita-KyutokuM, YuriT, UeharaN, TsuburaA. Effects of maternal xenoestrogen exposure on development of the reproductive tract and mammary gland in female CD-1 mouse offspring. Reprod Toxicol, 18:803–811. 2004.
299.
NiuG, WrightKL, MaY, WrightGM, HuangM, IrbyR, BriggsJ, KarrasJ, CressWD, PardollD, JoveR, ChenJ, YuH. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol, 25:7432–7440. 2005.
300.
NotasG, NifliAP, KampaM, VercauterenJ, KouroumalisE, CastanasE. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta, 1760:1657–1666. 2006.
301.
NovakovicA, BukaricaLG, KanjuhV, HeinleH. Potassium channels-mediated vasorelaxation of rat aorta induced by resveratrol. Basic Clin Pharmacol Toxicol, 99:360–364. 2006.
302.
OhshiroK, RayalaSK, El-NaggarAK, KumarR. Delivery of cytoplasmic proteins to autophagosomes. Autophagy, 4:104–106. 2008.
303.
OlsonER, NaugleJE, ZhangX, BomserJA, MeszarosJG. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol, 288:H1131–1138. 2005.
304.
OnoM, KuwanoM. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res, 12:7242–7251. 2006.
305.
OpipariAWJr, TanL, BoitanoAE, SorensonDR, AuroraA, LiuJR. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res, 64:696–703. 2004.
306.
OralloF, AlvarezE, CaminaM, LeiroJM, GomezE, FernandezP. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol, 61:294–302. 2002.
307.
OrsiniF, VerottaL, LecchiM, RestanoR, CuriaG, RedaelliE, WankeE. Resveratrol derivatives and their role as potassium channels modulators. J Nat Prod, 67:421–426. 2004.
308.
OvesnaZ, Horvathova-KozicsK. Structure-activity relationship of trans-resveratrol and its analogues. Neoplasma, 52:450–455. 2005.
309.
OwuorED, KongAN. Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol, 64:765–770. 2002.
310.
ParkCE, KimMJ, LeeJH, MinBI, BaeH, ChoeW, KimSS, HaJ. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med, 39:222–229. 2007.
311.
ParkSY, JeongKJ, LeeJ, YoonDS, ChoiWS, KimYK, HanJW, KimYM, KimBK, LeeHY. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett, 258:63–69. 2007.
PearceVP, SherrellJ, LouZ, KopelovichL, WrightWE, ShayJW. Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene, 27:2365–2374. 2008.
314.
PellegattaF, BertelliAA, StaelsB, DuhemC, FulgenziA, FerreroME. Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. Am J Clin Nutr, 77:1220–1228. 2003.
315.
PerroneG, NicolettiI, PascaleM, RossiAD, GirolamoAD, ViscontiA. Positive correlation between high levels of ochratoxin A and resveratrol-related compounds in red wines. J Agric Food Chem, 55:6807–6812. 2007.
316.
PersichiniT, CantoniO, SuzukiH, ColasantiM. Cross-talk between constitutive and inducible NO synthase: an update. Antioxid Redox Signal, 8:949–954. 2006.
317.
PervaizS. Resveratrol: from grapevines to mammalian biology. FASEB J, 17:1975–1985. 2003.
PervaizS, ClementMV. Tumor intracellular redox status and drug resistance: serendipity or a causal relationship?Curr Pharm Des, 10:1969–1977. 2004.
320.
PetitjeanA, MatheE, KatoS, IshiokaC, TavtigianSV, HainautP, OlivierM. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat, 28:622–629. 2007.
321.
PicardF, KurtevM, ChungN, Topark-NgarmA, SenawongT, Machado De OliveiraR, LeidM, McBurneyMW, GuarenteL. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature, 429:771–776. 2004.
322.
PignatelliP, GhiselliA, BuchettiB, CarnevaleR, NatellaF, GermanoG, FimognariF, Di SantoS, LentiL, VioliF. Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Atherosclerosis, 188:77–83. 2006.
323.
PintoMC, Garcia-BarradoJA, MaciasP. Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenase. J Agric Food Chem, 47:4842–4846. 1999.
324.
PirolaL, FrojdoS. Resveratrol: one molecule, many targets. IUBMB Life, 60:323–332. 2008.
325.
PoolmanTM, NgLL, FarmerPB, MansonMM. Inhibition of the respiratory burst by resveratrol in human monocytes: correlation with inhibition of PI3K signaling. Free Radic Biol Med, 39:118–132. 2005.
326.
PouyssegurJ, DayanF, MazureNM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 441:437–443. 2006.
327.
Pozo-GuisadoE, Lorenzo-BenayasMJ, Fernandez-SalgueroPM. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer, 109:167–173. 2004.
328.
Pozo-GuisadoE, MerinoJM, Mulero-NavarroS, Lorenzo-BenayasMJ, CentenoF, Alvarez-BarrientosA, Fernandez-SalgueroPM. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer, 115:74–84. 2005.
329.
ProzorovskiT, Schulze-TopphoffU, GlummR, BaumgartJ, SchroterF, NinnemannO, SiegertE, BendixI, BrustleO, NitschR, ZippF, AktasO. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol, 10:385–394. 2008.
330.
PuissantA, GrossoS, JacquelA, BelhaceneN, ColosettiP, CassutoJP, AubergerP. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J, 22:1894–1904. 2008.
331.
QueirozAN, GomesBA, MoraesWMJr, BorgesRS. A theoretical antioxidant pharmacophore for resveratrol. Eur J Med Chem, 44:1644–1649. 2009.
332.
Quincozes-SantosA, AndreazzaAC, NardinP, FunchalC, GoncalvesCA, GottfriedC. Resveratrol attenuates oxidative-induced DNA damage in C6 glioma cells. Neurotoxicology, 28:886–891. 2007.
333.
QuineyC, DauzonneD, KernC, FourneronJD, IzardJC, MohammadRM, KolbJP, BillardC. Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells. Leuk Res, 28:851–861. 2004.
334.
QuinonesA, DobbersteinKU, RainovNG. The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. Life Sci, 72:2975–2992. 2003.
335.
RadkarV, Lau-CamC, HardejD, BillackB. The role of surface receptor stimulation on the cytotoxicity of resveratrol to macrophages. Food Chem Toxicol, 46:3664–3670. 2008.
336.
RagioneFD, CucciollaV, CrinitiV, IndacoS, BorrielloA, ZappiaV. p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem, 278:23360–23368. 2003.
337.
Reagan-ShawS, AfaqF, AzizMH, AhmadN. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene, 23:5151–5160. 2004.
338.
ReinhardtHC, AslanianAS, LeesJA, YaffeMB. p53-Deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 11:175–189. 2007.
339.
RenaudS, de LorgerilM. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet, 339:1523–1526. 1992.
340.
RobbEL, WinkelmolenL, VisanjiN, BrotchieJ, StuartJA. Dietary resveratrol administration increases MnSOD expression and activity in mouse brain. Biochem Biophys Res Commun, 372:254–259. 2008.
341.
RochefortH, GarciaM, GlonduM, LaurentV, LiaudetE, ReyJM, RogerP. Cathepsin D in breast cancer: mechanisms and clinical applications: a 1999 overview. Clin Chim Acta, 291:157–170. 2000.
342.
RomanV, BillardC, KernC, Ferry-DumazetH, IzardJC, MohammadR, MossalayiDM, KolbJP. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br J Haematol, 117:842–851. 2002.
343.
RossD. Quinone reductases multitasking in the metabolic world. Drug Metab Rev, 36:639–654. 2004.
344.
RuefJ, MoserM, KublerW, BodeC. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol, 10:311–315. 2001.
345.
SachdevS, DaviesKJ. Production, detection, and adaptive responses to free radicals in exercise. Free Radic Biol Med, 44:215–223. 2008.
346.
SaijonmaaO, NymanT, KosonenR, FyhrquistF. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol, 280:H885–H891. 2001.
347.
SalaG, MinutoloF, MacchiaM, SacchiN, GhidoniR. Resveratrol structure and ceramide-associated growth inhibition in prostate cancer cells. Drugs Exp Clin Res, 29:263–269. 2003.
348.
SallmanDA, ChenX, ZhongB, GilvaryDL, ZhouJ, WeiS, DjeuJY. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther, 6:2938–2947. 2007.
349.
SareenD, DarjatmokoSR, AlbertDM, PolansAS. Mitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol Pharmacol, 72:1466–1475. 2007.
350.
SareenD, van GinkelPR, TakachJC, MohiuddinA, DarjatmokoSR, AlbertDM, PolansAS. Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Invest Ophthalmol Vis Sci, 47:3708–3716. 2006.
351.
SarkarFH, LiY. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci, 13:2950–2959. 2008.
352.
SattirajuS, ReyesS, KaneGC, TerzicA. K(ATP) channel pharmacogenomics: from bench to bedside. Clin Pharmacol Ther, 83:354–357. 2008.
ScarlattiF, MaffeiR, BeauI, CodognoP, GhidoniR. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ, 15:1318–1329. 2008.
355.
ScarlattiF, SalaG, RicciC, MaioliC, MilaniF, MinellaM, BotturiM, GhidoniR. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett, 253:124–130. 2007.
356.
ScarlattiF, SalaG, SomenziG, SignorelliP, SacchiN, GhidoniR. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J, 17:2339–2341. 2003.
357.
Scherz-ShouvalR, ShvetsE, ElazarZ. Oxidation as a post-translational modification that regulates autophagy. Autophagy, 3:371–373. 2007.
358.
Scherz-ShouvalR, ShvetsE, FassE, ShorerH, GilL, ElazarZ. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J, 26:1749–1760. 2007.
359.
SeemannS, HainautP. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene, 24:3853–3863. 2005.
360.
SehgalPB. STAT-signalling through the cytoplasmic compartment: consideration of a new paradigm. Cell Signal, 12:525–535. 2000.
SerreroG, LuR. Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid Redox Signal, 3:969–979. 2001.
363.
SettlemanJ. PAK-in' up cGMP for the move. Cell, 128:237–238. 2007.
364.
SeveM, ChimientiF, DevergnasS, AouffenM, DoukiT, ChantegrelJ, CadetJ, FavierA. Resveratrol enhances UVA-induced DNA damage in HaCaT human keratinocytes. Med Chem, 1:629–633. 2005.
365.
ShankarS, SiddiquiI, SrivastavaRK. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem, 304:273–285. 2007.
366.
SheQB, BodeAM, MaWY, ChenNY, DongZ. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res, 61:1604–1610. 2001.
367.
SheQB, HuangC, ZhangY, DongZ. Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog, 33:244–250. 2002.
368.
ShenF, ChenSJ, DongXJ, ZhongH, LiYT, ChengGF. Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. J Asian Nat Prod Res, 5:151–157. 2003.
ShibataMA, AkaoY, ShibataE, NozawaY, ItoT, MishimaS, MorimotoJ, OtsukiY. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother Pharmacol, 60:681–691. 2007.
371.
ShihA, ZhangS, CaoHJ, BoswellS, WuYH, TangHY, LennartzMR, DavisFB, DavisPJ, LinHY. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol Cancer Ther, 3:1355–1364. 2004.
372.
SibiliaM, KroismayrR, LichtenbergerBM, NatarajanA, HeckingM, HolcmannM. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation, 75:770–787. 2007.
373.
SinghNP, HegdeVL, HofsethLJ, NagarkattiM, NagarkattiP. Resveratrol (trans-3,5,4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol, 72:1508–1521. 2007.
374.
SinghP, MittalA. Current status of COX-2 inhibitors. Mini Rev Med Chem, 8:73–90. 2008.
375.
SlaterSJ, SeizJL, CookAC, StaglianoBA, BuzasCJ. Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta, 1637:59–69. 2003.
376.
SmithBC, HallowsWC, DenuJM. Mechanisms and molecular probes of sirtuins. Chem Biol, 15:1002–1013. 2008.
377.
SolansA, ZambranoA, RodriguezM, BarrientosA. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet, 15:3063–3081. 2006.
378.
SoleasGJ, DiamandisEP, GoldbergDM. Resveratrol: a molecule whose time has come? And gone?Clin Biochem, 30:91–113. 1997.
379.
SonYH, JeongYT, LeeKA, ChoiKH, KimSM, RhimBY, KimK. Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol, 51:71–77. 2008.
380.
SongJJ, LeeYJ. Catalase, but not MnSOD, inhibits glucose deprivation-activated ASK1-MEK-MAPK signal transduction pathway and prevents relocalization of Daxx: hydrogen peroxide as a major second messenger of metabolic oxidative stress. J Cell Biochem, 90:304–314. 2003.
381.
SongJJ, LeeYJ. Effect of glucose concentration on activation of the ASK1-SEK1-JNK1 signal transduction pathway. J Cell Biochem, 89:653–662. 2003.
382.
SongLH, PanW, YuYH, QuarlesLD, ZhouHH, XiaoZS. Resveratrol prevents CsA inhibition of proliferation and osteoblastic differentiation of mouse bone marrow-derived mesenchymal stem cells through an ER/NO/cGMP pathway. Toxicol In Vitro, 20:915–922. 2006.
383.
St-PierreJ, DroriS, UldryM, SilvaggiJM, RheeJ, JagerS, HandschinC, ZhengK, LinJ, YangW, SimonDK, BachooR, SpiegelmanBM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127:397–408. 2006.
384.
StewartJR, O'BrianCA. Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs, 22:107–117. 2004.
385.
StivalaLA, SavioM, CarafoliF, PeruccaP, BianchiL, MagaG, FortiL, PagnoniUM, AlbiniA, ProsperiE, VanniniV. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem, 276:22586–22594. 2001.
386.
StorzP, DopplerH, TokerA. Activation loop phosphorylation controls protein kinase D-dependent activation of nuclear factor kappaB. Mol Pharmacol, 66:870–879. 2004.
387.
StuartJA, KarahalilB, HogueBA, Souza-PintoNC, BohrVA. Mitochondrial and nuclear DNA base excision repair are affected differently by caloric restriction. FASEB J, 18:595–597. 2004.
388.
SuJL, YangCY, ZhaoM, KuoML, YenML. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem, 282:19385–19398. 2007.
389.
SubausteAR, BurantCF. Role of FoxO1 in FFA-induced oxidative stress in adipocytes. Am J Physiol Endocrinol Metab, 293:E159–E164. 2007.
390.
SubbaramaiahK, ChungWJ, MichaluartP, TelangN, TanabeT, InoueH, JangM, PezzutoJM, DannenbergAJ. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem, 273:21875–21882. 1998.
391.
SubramanianM, ShadakshariU, ChattopadhyayS. A mechanistic study on the nuclease activities of some hydroxystilbenes. Bioorg Med Chem, 12:1231–1237. 2004.
392.
SuenagaF, HatsushikaK, TakanoS, AndoT, OhnumaY, OgawaH, NakaoA. A possible link between resveratrol and TGF-beta: resveratrol induction of TGF-beta expression and signaling. FEBS Lett, 582:586–590. 2008.
SundaresanNR, SamantSA, PillaiVB, RajamohanSB, GuptaMP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol, 28:6384–6401. 2008.
395.
SuzukiK, KoikeT. Resveratrol abolishes resistance to axonal degeneration in slow Wallerian degeneration (WldS) mice: activation of SIRT2, an NAD-dependent tubulin deacetylase. Biochem Biophys Res Commun, 359:665–671. 2007.
396.
SzewczukLM, FortiL, StivalaLA, PenningTM. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem, 279:22727–22737. 2004.
397.
SzewczukLM, LeeSH, BlairIA, PenningTM. Viniferin formation by COX-1: evidence for radical intermediates during co-oxidation of resveratrol. J Nat Prod, 68:36–42. 2005.
398.
SzkudelskiT. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. Am J Physiol Endocrinol Metab, 293:E901–E907. 2007.
399.
TanakaT, HuangX, HalickaHD, ZhaoH, TraganosF, AlbinoAP, DaiW, DarzynkiewiczZ. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A, 71:648–661. 2007.
400.
TangHY, ShihA, CaoHJ, DavisFB, DavisPJ, LinHY. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther, 5:2034–2042. 2006.
401.
TangX, ZhangQ, NishitaniJ, BrownJ, ShiS, LeAD. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res, 13:2568–2576. 2007.
402.
TappiaPS, DentMR, DhallaNS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med, 41:349–361. 2006.
403.
ThomasDD, RidnourLA, IsenbergJS, Flores-SantanaW, SwitzerCH, DonzelliS, HussainP, VecoliC, PaolocciN, AmbsS, ColtonCA, HarrisCC, RobertsDD, WinkDA. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med, 45:18–31. 2008.
404.
TianB, YangQ, MaoZ. Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death. Nat Cell Biol, 11:211–218. 2009.
405.
TisdaleMJ. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol, 3:209–217. 2005.
406.
TissenbaumHA, GuarenteL. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature, 410:227–230. 2001.
TrincheriNF, FolloC, NicotraG, PeracchioC, CastinoR, IsidoroC. Resveratrol-induced apoptosis depends on the lipid kinase activity of Vps34 and on the formation of autophagolysosomes. Carcinogenesis, 29:381–389. 2008.
410.
TrincheriNF, NicotraG, FolloC, CastinoR, IsidoroC. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis, 28:922–931. 2007.
411.
TsaiSH, Lin-ShiauSY, LinJK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol, 126:673–680. 1999.
412.
TyagiA, SinghRP, AgarwalC, SiriwardanaS, SclafaniRA, AgarwalR. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis, 26:1978–1987. 2005.
413.
UhleS, MedaliaO, WaldronR, DumdeyR, HenkleinP, Bech-OtschirD, HuangX, BerseM, SperlingJ, SchadeR, DubielW. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J, 22:1302–1312. 2003.
414.
UlrichS, HuwilerA, LoitschS, SchmidtH, SteinJM. De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. Biochem Pharmacol, 74:281–289. 2007.
415.
UshaS, JohnsonIM, MalathiR. Interaction of resveratrol and genistein with nucleic acids. J Biochem Mol Biol, 38:198–205. 2005.
416.
UshaS, JohnsonIM, MalathiR. Modulation of DNA intercalation by resveratrol and genistein. Mol Cell Biochem, 284:57–64. 2006.
417.
UshaS, JohnsonIM, MalathiR. Possible inhibition of group I intron RNA by resveratrol and genistein. J Biomol Struct Dyn, 24:25–32. 2006.
418.
van de WeteringK, BurkonA, FeddemaW, BotA, de JongeH, SomozaV, BorstP. Intestinal BCRP/Bcrp1 and MRP3/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol, 75:876–885. 2009.
419.
Vanden BergheT, DeclercqW, VandenabeeleP. NADPH oxidases: new players in TNF-induced necrotic cell death. Mol Cell, 26:769–771. 2007.
420.
VellaF, FerryG, DelagrangeP, BoutinJA. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol, 71:1–12. 2005.
421.
VenkatachalamK, MummidiS, CortezDM, PrabhuSD, ValenteAJ, ChandrasekarB. Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. Am J Physiol Heart Circ Physiol, 294:H2078–H2087. 2008.
422.
VenkatesanB, Ghosh-ChoudhuryN, DasF, MahimainathanL, KamatA, KasinathBS, AbboudHE, ChoudhuryGG. Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J, 22:3469–3482. 2008.
423.
VitracX, DesmouliereA, BrouillaudB, KrisaS, DeffieuxG, BartheN, RosenbaumJ, MerillonJM. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci, 72:2219–2233. 2003.
424.
VyasS, AsmeromY, De LeonDD. Insulin-like growth factor II mediates resveratrol stimulatory effect on cathepsin D in breast cancer cells. Growth Factors, 24:79–87. 2006.
425.
WadsworthTL, KoopDR. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem Pharmacol, 57:941–949. 1999.
426.
WangJ, WangJ, DaiJ, JungY, WeiCL, WangY, HavensAM, HoggPJ, KellerET, PientaKJ, NorJE, WangCY, TaichmanRS. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res, 67:149–159. 2007.
427.
WangRH, SenguptaK, LiC, KimHS, CaoL, XiaoC, KimS, XuX, ZhengY, ChiltonB, JiaR, ZhengZM, AppellaE, WangXW, RiedT, DengCX. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 14:312–323. 2008.
428.
WangRH, ZhengY, KimHS, XuX, CaoL, LuhasenT, LeeMH, XiaoC, VassilopoulosA, ChenW, GardnerK, ManYG, HungMC, FinkelT, DengCX. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell, 32:11–20. 2008.
429.
WangS, WangX, YanJ, XieX, FanF, ZhouX, HanL, ChenJ. Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: correlated with NO-cGMP signaling pathway. Eur J Pharmacol, 567:26–35. 2007.
430.
WangTT, HudsonTS, WangTC, RemsbergCM, DaviesNM, TakahashiY, KimYS, SeifriedH, VinyardBT, PerkinsSN, HurstingSD. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis, 29:2001–2010. 2008.
431.
WeaverBA, SilkAD, MontagnaC, Verdier-PinardP, ClevelandDW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell, 11:25–36. 2007.
432.
WeydtP, PinedaVV, TorrenceAE, LibbyRT, SatterfieldTF, LazarowskiER, GilbertML, MortonGJ, BammlerTK, StrandAD, CuiL, BeyerRP, EasleyCN, SmithAC, KraincD, LuquetS, SweetIR, SchwartzMW, La SpadaAR. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab, 4:349–362. 2006.
433.
WolterF, TurchanowaL, SteinJ. Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis, 24:469–474. 2003.
434.
WooJH, LimJH, KimYH, SuhSI, MinDS, ChangJS, LeeYH, ParkJW, KwonTK. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene, 23:1845–1853. 2004.
435.
WooKJ, LeeTJ, LeeSH, LeeJM, SeoJH, JeongYJ, ParkJW, KwonTK. Elevated gadd153/chop expression during resveratrol-induced apoptosis in human colon cancer cells. Biochem Pharmacol, 73:68–76. 2007.
436.
WuCP, CalcagnoAM, HladkySB, AmbudkarSV, BarrandMA. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5)FEBS J, 272:4725–4740. 2005.
WuSL, SunZJ, YuL, MengKW, QinXL, PanCE. Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol, 10:3048–3052. 2004.
439.
WungBS, HsuMC, WuCC, HsiehCW. Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sci, 78:389–397. 2005.
440.
WykeSM, RussellST, TisdaleMJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer, 91:1742–1750. 2004.
441.
XuW, NgoL, PerezG, DokmanovicM, MarksPA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A, 103:15540–15545. 2006.
442.
YamadaM, HayashiK, HayashiH, TsujiR, KakumotoK, IkedaS, HoshinoT, TsutsuiK, ItoT, IinumaM, NozakiH. Nepalensinols D-G, new resveratrol oligomers from Kobresia nepalensis (Cyperaceae) as potent inhibitors of DNA topoisomerase II. Chem Pharm Bull (Tokyo), 54:354–358. 2006.
443.
YangS, IraniK, HeffronSE, JurnakF, MeyskensFLJr. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther, 4:1923–1935. 2005.
444.
YeungF, HobergJE, RamseyCS, KellerMD, JonesDR, FryeRA, MayoMW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J, 23:2369–2380. 2004.
445.
YingW. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal, 10:179–206. 2008.
446.
YounHS, LeeJY, FitzgeraldKA, YoungHA, AkiraS, HwangDH. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol, 175:3339–3346. 2005.
447.
Zamora-RosR, Urpi-SardaM, Lamuela-RaventosRM, EstruchR, Martinez-GonzalezMA, BulloM, ArosF, CherubiniA, Andres-LacuevaC. Resveratrol metabolites in urine as a biomarker of wine intake in free-living subjects: the PREDIMED Study. Free Radic Biol Med, 46:1562–1566. 2009.
448.
ZhangH, KimJK, EdwardsCA, XuZ, TaichmanR, WangCY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol, 7:909–915. 2005.
449.
ZhangLP, YinJX, LiuZ, ZhangY, WangQS, ZhaoJ. Effect of resveratrol on L-type calcium current in rat ventricular myocytes. Acta Pharmacol Sin, 27:179–183. 2006.
450.
ZhangP, LiH, WuML, ChenXY, KongQY, WangXW, SunY, WenS, LiuJ. c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells. J Neurooncol, 80:123–131. 2006.
451.
ZhangQ, TangX, LuQY, ZhangZF, BrownJ, LeAD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther, 4:1465–1474. 2005.
452.
ZhouSF, XueCC, YuXQ, WangG. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab, 8:526–553. 2007.
453.
ZhouT, XuL, DeyB, HessellAJ, Van RykD, XiangSH, YangX, ZhangMY, ZwickMB, ArthosJ, BurtonDR, DimitrovDS, SodroskiJ, WyattR, NabelGJ, KwongPD. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature, 445:732–737. 2007.
